A Multi‐Center Real‐World Study of Clinicopathologic Characteristics and Efficacy of the Malignant Mesothelioma in Chinese Population
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.15533 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Chenrui Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing…. Hauptthemen laut MEDLINE: Mesothelioma, Malignant, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Objective
Malignant mesothelioma (MM) is a rare malignant tumor. To explore the clinicopathological characteristics and efficacy of Chinese population with MM in the real‐world.
Methods
Two hundred and forty‐eight patients diagnosed with MM between September 2007 and August 2024 from three large medical centers (Beijing Hospital, Peking University Cancer Hospital, and Chinese Academy of Medical Sciences Cancer Hospital) were retrospectively analyzed. Kaplan–Meier and Cox regression were performed. Breast cancer gene 1‐associated protein 1 ( BAP1 ) status was evaluated.
Results
Chinese population with MM had a lower diagnostic age, higher proportion of youth and female, more advanced stage and lower expression of characteristic markers. The median progression‐free survival (mPFS) and median overall survival (mOS) were 8.90 and 25.60 months for the first‐line treatment, and 3.28 and 19.50 months for the second‐line. The first‐line immunotherapy provided a relatively higher objective response rate (33.3% vs. 20.5%, p = 0.402) and a trend to prolong mPFS (12.10 vs. 9.20 months, p = 0.345) and mOS (NA vs. 23.90, p = 0.185) compared with chemotherapy. Bevacizumab combined with chemotherapy relatively prolonged mPFS (10.47 vs. 7.93 months, p = 0.074) and mOS (31.30 vs. 23.20 months, p = 0.673) than chemotherapy alone. Carboplatin relatively improved mPFS than cisplatin (10.87 vs. 8.87 months, p = 0.185). Age and histologic type were predictors for PFS, and gender, histologic subtype, and CK5/6 were prognosis factors for OS. Briefly, 17.78% patients existed BAP1 deletions and correlated with OS benefit.
Conclusion
Chinese population with MM present unique clinicopathologic characteristics and could benefit from the first‐line immunotherapy and bevacizumab combined with chemotherapy. Gender, histologic subtype, and CK5/6 are prognosis factors for OS. BAP1 deletions correlate with OS benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Pathology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China.
- Department of Oncology, Binzhou Medical University Hospital, Binzhou, China.
ORCID-Profile: Chenrui Sun, Xue Yang, Zhixin Bie, Bin Ai, Jia Zhong, Jiangyong Yu
Förderung
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Sun, C., Yang, X., Chen, L., Bie, Z., Kang, R., Ai, B., Ma, J., Zheng, Z., Liu, H., Liu, J., Zhong, J., & Yu, J. (2025). A Multi‐Center Real‐World Study of Clinicopathologic Characteristics and Efficacy of the Malignant Mesothelioma in Chinese Population. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15533
Vancouver
Sun C, Yang X, Chen L, Bie Z, Kang R, Ai B, et al. A Multi‐Center Real‐World Study of Clinicopathologic Characteristics and Efficacy of the Malignant Mesothelioma in Chinese Population. Thoracic Cancer. 2025. doi:10.1111/1759-7714.15533
BibTeX
@article{Sun2025,
author = {Sun, Chenrui and Yang, Xue and Chen, Lan and Bie, Zhixin and Kang, Runting and Ai, Bin and Ma, Junling and Zheng, Zitong and Liu, Haolan and Liu, Juanjuan and Zhong, Jia and Yu, Jiangyong},
title = {A Multi‐Center Real‐World Study of Clinicopathologic Characteristics and Efficacy of the Malignant Mesothelioma in Chinese Population},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.15533}
}
EUVIMED